Targeting breast cancer stem cells with HER2-specific antibodies and natural killer cells.

Abstract

Breast cancer is the most common cancer among women worldwide. Every year, nearly 1.4 million new cases of breast cancer are diagnosed, and about 450.000 women die of the disease. Approximately 15-25% of breast cancer cases exhibit increased quantities of the trans-membrane receptor tyrosine kinase human epidermal growth factor receptor 2 (HER2) on the… (More)

Topics

  • Presentations referencing similar topics